Literature DB >> 33270370

Corrigendum.

.   

Abstract

Entities:  

Year:  2020        PMID: 33270370      PMCID: PMC8182953          DOI: 10.1002/npr2.12148

Source DB:  PubMed          Journal:  Neuropsychopharmacol Rep        ISSN: 2574-173X


× No keyword cloud information.
In the article by Takahashi et al, the term “Morisky Medication Adherence Scale‐4 items (MMAS‐4)” in the last row of Table 1 should read as "Morisky Simplified Self‐Report Measure of Adherence" and the abbreviation “MMAS‐4” in the table legend should be deleted.
TABLE 1

Demographic and clinical characteristics of patients

CharacteristicsValues
Age, years46.6 ± 12.5
Male sex49 (54.4)
Inpatients41 (45.6)
Duration of illness, years20.3 ± 13.8
Duration of treatment, years17.2 ± 13.6
History of LAI use26 (28.9)
PANSS
Total score72.8 ± 18.7
Positive symptoms score16.6 ± 5.5
Negative symptoms score19.5 ± 6.1
General psychopathology score36.7 ± 9.3
PDQ total score25.9 ± 14.4
VAGUS total score6.4 ± 1.7
DAI‐10 total score3.4 ± 4.9
Morisky Simplified Self‐Report Measure of Adherence1.6 ± 1.2

Values are shown as mean ± standard deviation (range) or n (%).

Abbreviations: DAI‐10, Drug Attitude Inventory‐10; LAI, Long‐acting injection; PANSS, Positive and Negative Syndrome Scale; PDQ, Perceived Deficits Questionnaire.

The corrected table is provided below, Demographic and clinical characteristics of patients Values are shown as mean ± standard deviation (range) or n (%). Abbreviations: DAI‐10, Drug Attitude Inventory‐10; LAI, Long‐acting injection; PANSS, Positive and Negative Syndrome Scale; PDQ, Perceived Deficits Questionnaire. The authors apologize for this error.
  1 in total

1.  Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study.

Authors:  Kie Takahashi; Ryoko Yamazawa; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Neuropsychopharmacol Rep       Date:  2020-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.